In addition, we analyzed several native CBF leukemia samples, known to highly express CD117 (KIT) and harboring gain-of-function mutations in 40% of cases: Samples were treated with crenolanib in a dose-dependent manner for 48 hours and reduction of the CD45-low viable cohort was followed. The gene discussed is CEBPZ; the disease is leukemia.